Effects of rivaroxaban on platelet activation and platelet-coagulation pathway interaction: In vitro and in vivo studies

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 20, Issue 6, 2015, Pages 554-562

  Perzborn, Elisabeth ^a   Heitmeier, Stefan ^a   Laux, Volker ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

antiplatelet agents; combination drug therapy; platelet aggregation; rivaroxaban; thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; RIVAROXABAN; THROMBIN; THROMBOPLASTIN; TICAGRELOR; ADENOSINE; ANTITHROMBOCYTIC AGENT; TICLOPIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTERIOVENOUS SHUNT; ARTERY THROMBOSIS; ARTICLE; BLOOD CLOTTING; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; FEMALE; HEMOSTASIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MALE; MONOTHERAPY; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; RAT; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE RICH PLASMA; ADULT; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; CORONARY ARTERY THROMBOSIS; DRUG EFFECTS; METABOLISM; WISTAR RAT;

ADENOSINE; ADULT; ANIMALS; ARTERIOVENOUS SHUNT, SURGICAL; ASPIRIN; BLOOD COAGULATION; CORONARY THROMBOSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; RATS; RATS, WISTAR; RIVAROXABAN; THROMBIN; TICLOPIDINE;

EID: 84943648606     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248415578172     Document Type: Article

References (36)

1. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation. 2012; 125 (1): e2-e220.
2. Anderson JL, Adams CD, Antman EM, et al. 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011; 123 (18): e426-e579.
3. Hamm CW, Bassand JP, Agewall S, et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the Management of Acute Coronary Syndromes (ACS) in Patients Presenting Without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2011; 32 (23): 2999-3054.
4. Libby P, Theroux P,. Pathophysiology of coronary artery disease. Circulation. 2005; 111 (25): 3481-3488.
5. Caughey GE, Cleland LG, Gamble JR, James MJ,. Up-regulation of endothelial cyclooxygenase-2 and prostanoid synthesis by platelets. Role of thromboxane A2. J Biol Chem. 2001; 276 (41): 37839-37845.
6. Sharma S, Sharma SC,. An update on eicosanoids and inhibitors of cyclooxygenase enzyme systems. Indian J Exp Biol. 1997; 35 (10): 1025-1031.
7. Ford ES, Ajani UA, Croft JB, et al. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med. 2007; 356 (23): 2388-2398.
8. Chew DP, Huynh LT, Liew D, Astley C, Soman A, Brieger D,. Potential survival gains in the treatment of myocardial infarction. Heart. 2009; 95 (22): 1844-1850.
9. Merlini PA, Bauer KA, Oltrona L, et al. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation. 1994; 90 (1): 61-68.
10. Steg PG, James SK, Atar D, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology (ESC). Eur Heart J. 2012; 33 (20): 2569-2619.
11. Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G,. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther. 2005; 78 (4): 412-421.
12. Perzborn E, Roehrig S, Straub A, Kubitza D, Misselwitz F,. The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor. Nat Rev Drug Discov. 2011; 10 (1): 61-75.
13. Perzborn E, Strassburger J, Wilmen A, et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939-an oral, direct factor Xa inhibitor. J Thromb Haemost. 2005; 3 (3): 514-521.
14. Gerotziafas GT, Elalamy I, Depasse F, Perzborn E, Samama MM,. In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban. J Thromb Haemost. 2007; 5 (4): 886-888.
15. Biemond BJ, Perzborn E, Friederich PW, Levi M, Buetehorn U, Büller HR,. Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 59-7939)-an oral, direct factor Xa inhibitor. Thromb Haemost. 2007; 97 (3): 471-477.
16. Wong PC, Crain EJ, Watson CA, Xin B,. Favorable therapeutic index of the direct factor Xa inhibitors, apixaban and rivaroxaban, compared to the thrombin inhibitor dabigatran in rabbits. J Thromb Haemost. 2009; 7 (8): 1313-1320.
17. Wagner NM, Dressel T, Schafer K, Konstantinides S,. Effect of the factor Xa inhibitor rivaroxaban on arterial thrombosis in wild-type and apolipoprotein E-deficient mice. Thromb Res. 2012; 130 (5): 793-798.
18. Parry TJ, Huang Z, Chen C, et al. Arterial antithrombotic activity of rivaroxaban, an orally active factor Xa inhibitor, in a rat electrolytic carotid artery injury model of thrombosis. Blood Coagul Fibrinolysis. 2011; 22 (8): 720-726.
19. Perzborn E, Strassburger J, Wilmen A, et al. Biochemical and pharmacologic properties of BAY 59-7939, an oral, direct factor Xa inhibitor. Pathophysiol Haemost Thromb. 2004; 33. Abstract PO079.
20. Fareed J, Hoppensteadt D, Maddenini J, et al. Antithrombotic mechanism of action of BAY 59-7939-a novel, oral, direct factor Xa inhibitor. J Thromb Haemost. 2005; 3: Abstract P0518.
21. Wong PC, Jiang X,. Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa and thrombin. Thromb Haemost. 2010; 104 (2): 302-310.
22. Monroe DM, Hoffman M,. What does it take to make the perfect clot? Arterioscler Thromb Vasc Biol. 2006; 26 (1): 41-48.
23. Herault JP, Dol F, Gaich C, Bernat A, Herbert JM,. Effect of clopidogrel on thrombin generation in platelet-rich plasma in the rat. Thromb Haemost. 1999; 81 (6): 957-960.
24. Berry CN, Girard D, Lochot S, Lecoffre C,. Antithrombotic actions of argatroban in rat models of venous, 'mixed' and arterial thrombosis, and its effects on the tail transection bleeding time. Br J Pharmacol. 1994; 113 (4): 1209-1214.
25. Peters RF, Lees CM, Mitchell KA, Tweed MF, Talbot MD, Wallis RB,. The characterisation of thrombus development in an improved model of arterio-venous shunt thrombosis in the rat and the effects of recombinant desulphatohirudin (CGP 39393), heparin, and iloprost. Thromb Haemost. 1991; 65 (3): 268-274.
26. Xu XS, Moore K, Burton P, et al. Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with acute coronary syndromes. Br J Clin Pharmacol. 2012; 74 (1): 86-97.
27. Vanschoonbeek K, Feijge MA, Van Kampen RJ, et al. Initiating and potentiating role of platelets in tissue factor-induced thrombin generation in the presence of plasma: subject-dependent variation in thrombogram characteristics. J Thromb Haemost. 2004; 2 (3): 476-484.
28. Ringwala SM, DiBattiste PM, Schneider DJ,. Effects on platelet function of a direct acting antagonist of coagulation factor Xa. J Thromb Thrombolysis. 2012; 34 (3): 291-296.
29. Seuter F,. Inhibition of platelet aggregation by acetylsalicylic acid and other inhibitors. Haemostasis. 1976; 5 (2): 85-95.
30. Sakariassen KS, Hanson SR, Cadroy Y,. Methods and models to evaluate shear-dependent and surface reactivity-dependent antithrombotic efficacy. Thromb Res. 2001; 104 (3): 149-174.
31. Vogel GM, Meuleman DG, Bourgondien FG, Hobbelen PM,. Comparison of two experimental thrombosis models in rats effects of four glycosaminoglycans. Thromb Res. 1989; 54 (5): 399-410.
32. Silvain J, Collet JP, Nagaswami C, et al. Composition of coronary thrombus in acute myocardial infarction. J Am Coll Cardiol. 2011; 57 (5): 1359-1367.
33. Becker EM, Perzborn E, Klipp A, et al. Effects of rivaroxaban, acetylsalicylic acid and clopidogrel as monotherapy and in combination in a porcine model of stent thrombosis. J Thromb Haemost. 2012; 10 (12): 2470-2480.
34. Weisshaar S, Litschauer B, Gouya G, et al. Antithrombotic triple therapy and coagulation activation at the site of thrombus formation: a randomized trial in healthy subjects. J Thromb Haemost. 2014; 12 (11): 1850-1860.
35. Wolzt M, Gouya G, Kapiotis S, Becka M, Mueck W, Kubitza D,. Open-label, randomized study of the effect of rivaroxaban with or without acetylsalicylic acid on thrombus formation in a perfusion chamber. Thromb Res. 2013; 132 (2): 240-247.
36. Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012; 366 (1): 9-19.